"Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen

Acta Biomedica de l'Ateneo Parmense

Volumn 75, Issue 2, 2004, Pages

  Giacosa, Roberto ^a   Santi, Rosaria ^a   Vaglio, Augusto ^a   Pavone, Laura ^a   Ferrozzi, Francesco ^b   Passalacqua, Rodolfo ^c   Buzio, Carlo ^a,d  

^a UNIVERSITY OF PARMA   (Italy)

^b Radiological Inst Figlie S Camillo   (Italy)

^c Oncology Division   (Italy)

^d Dipto Clin Med Nefrol/Sci Prev   (Italy)

Author keywords

Immunotherapy; Interferon ; Interleukin 2; Metastatic renal cell cancer; Tumour regression

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; HUMAN; IMMUNOTHERAPY; KIDNEY CANCER; LOW DRUG DOSE; LUNG METASTASIS; MALE; METASTASIS; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FATAL OUTCOME; HEART NEOPLASMS; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; RECOMBINANT PROTEINS; REMISSION INDUCTION; SHOCK, CARDIOGENIC; TIME FACTORS;

EID: 19444380356     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bumpus HC. The apparent disappearance of pulmonary metastasis in a case of hypernephroma following nephrectomy. J Urol 1928; 20: 185-91.
2. Fairlamb DJ. Spontaneous regression of metastases of renal cancer: a report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 1981; 47: 2102-6.
3. Snow RM, Schellhammer PF. Spontaneous regression of metastatic renal cell carcinoma. Urology 1982; 20: 177-81.
4. Young RC. Metastatic renal-cell carcinoma: what causes occasional dramatic regressions? N Engl J Med 1998; 338: 1305-6.
5. Everson TC, Cole WH. Spontaneous regression of cancer. WB Saunders Co.: Philadelphia, 1966, 11-87.
6. Buzio C, et al. Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br J Cancer 1997; 76: 541-4.
7. Buzio C, et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in advanced renal cell cancer. Cancer 2001: 92: 2286-96.
8. TNM classification of malignant tumours. Fifth edition. So bin LH and Wittekind, Ch, eds. Wiley-Liss, New York, 1997, 198-200.
9. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-63.
10. Ljunggren E, Holm S, Karth B, Pompeius R. Some aspects of renal tumours with special reference to spontaneous regression. J Urol 1959; 82: 553-7.
11. Robinson CE. Spontaneous regression in renal carcinoma. Can Med Assoc J 1969; 100: 297-300.
12. MacManus MP, Harte RJ, Stranex S. Spontaneous regression of metastatic renal cell carcinoma following palliative irradiation of the primary tumour. Ir J Med Sci 1994; 163: 461-3.
13. Mohr SJ, Whitesel JA. Spontaneous regression of renal cell carcinoma metastases after preoperative embolization of primary tumor and subsequent nephrectomy. Urology 1979: 14; 5-8.
14. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon alpha-2b in advanced human malignancies. Lancet 1990; 335: 1509-12.
15. Vlasveld LT, et al. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects. Br J Cancer 1992; 65: 744-50.
16. Yang JC, et al. Randomized comparison of high dose and low dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994; 12: 1572-76.
17. Vlasveld LT, et al. A Phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects. Br J Cancer 1993; 68: 559-67
18. Caligiuri MA. Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Semin Oncol 1993; 20: 3-10
19. Uhr JV, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 1997; 3: 505-9